Jump to main content
Jump to site search

Issue 39, 2015
Previous Article Next Article

Protein-based photothermal theranostics for imaging-guided cancer therapy

Author affiliations

Abstract

The development of imageable photothermal theranostics has attracted considerable attention for imaging guided photothermal therapy (PTT) with high tumor ablation accuracy. In this study, we strategically constructed a near-infrared (NIR) cyanine dye by introducing a rigid cyclohexenyl ring to the heptamethine chain to obtain a heptamethine dye CySCOOH with high fluorescence intensity and good stability. By covalent conjugation of CySCOOH onto human serum albumin (HSA), the as-prepared HSA@CySCOOH nanoplatform is highly efficient for NIR fluorescence/photoacoustic/thermal multimodality imaging and photothermal tumor ablation. The theranostic capability of HSA@CySCOOH was systematically evaluated both in vitro and in vivo. Most intriguingly, complete tumor elimination was achieved by intravenous injection of HSA@CySCOOH (CySCOOH, 1 mg kg−1; 808 nm, 1.0 W cm−2 for 5 min) into 4T1 tumor-bearing mice, with no weight loss, noticeable toxicity, or tumor recurrence being observed. This as-prepared protein-based nanotheranostics exhibits high water dispersibility, no off target cytotoxicity, and good biodegradability and biocompatibility, thus facilitating its clinical translation to cancer photothermal theranostics.

Graphical abstract: Protein-based photothermal theranostics for imaging-guided cancer therapy

Back to tab navigation

Supplementary files

Article information


Submitted
10 Jul 2015
Accepted
22 Aug 2015
First published
02 Sep 2015

Nanoscale, 2015,7, 16330-16336
Article type
Paper
Author version available

Protein-based photothermal theranostics for imaging-guided cancer therapy

P. Rong, P. Huang, Z. Liu, J. Lin, A. Jin, Y. Ma, G. Niu, L. Yu, W. Zeng, W. Wang and X. Chen, Nanoscale, 2015, 7, 16330
DOI: 10.1039/C5NR04428F

Social activity

Search articles by author

Spotlight

Advertisements